Psychedelics

This may be a pivotal moment in the history of psychedelics...

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

As we enter the second coming of psychedelics popularity, H. Steven Moffic, MD, looks ahead to their third coming. Will it be similar to that of Dune?

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared with intravenous DMT for treatment-resistant depression.

Here are some updates from the world of psychiatry throughout the month of February.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

The treatment's PDUFA date is set for August 11, 2024.

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of December.

Reviewing a year of CMEs in Psychiatric Times®

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

Ketamine for anxiety? Researchers performed a systematic review and meta-analysis of ketamine’s anxiolytic effects.

What is new in research on psychedelics?

Here are some updates from the world of psychiatry throughout the month of October.

Residues of past traumatic events can deeply impact our present experiences and our functioning in ways that we are not aware of consciously. We must process and let go of these experiences in order to heal.

From new research on treatment-resistant major depression to strategies for supporting trauma-affected refugee youth, here are highlights from the week in Psychiatric Times.

Get ready for our upcoming virtual, interactive conference with some highlights from 2022.

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

What is new in research on psychedelics?

Do SSRIs impact on the antidepressant efficacy of psilocybin? Researchers performed an open-label trial of single-dose psilocybin in patients with TRD who were taking SSRIs.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.

The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.

In this CME article, learn more about the best practices for engaging patients in the informed consent process for psychedelic treatment and psychedelic-assisted psychotherapy.

From the brain-gut connection to neurocognitive and neuropsychiatric symptoms of long COVID, here are highlights from the week in Psychiatric Times.

A phase 2A trial recently received confirmation to proceed in investigating psilocybin-assisted psychotherapy in the treatment of adult patients with IBS.